Your search history is turned on.
Date: February 12, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario, Quebec
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Numb...
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights Projected Cash Runway Extends into Second Calendar Quarter 2026, Well Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application (NDA) Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial Continues, On Track for NDA Submission Timeline Poster Highlighting the STRIVE-ON Trial Prese...
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Robert DelAversano, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Acasti Pharma Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances ...
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Prashant Kohli, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Acasti Pharma Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances unde...
19 Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operation This managements discussion and analysis (MD&A) is presented in order to provide the reader with an overview of the financial results and changes to our consolidated balance sheet at December 31, 2023. This MD&A also explains the material variations in our results of operations for t...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT O...
Date: January 8, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario, Quebec
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2024 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Numbe...
Date: December 15, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario, Quebec
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2023 ACASTI PHARMA INC. (Exact name of Registrant as Specified in Its Charter) Quebec 001-35776 98-1359336 (State or Other Jurisdiction of Incorporation) (Commission File Numb...
Date: November 13, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario, Quebec
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Brian Ford, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Acasti Pharma Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under wh...